COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    urovant | URO-902
Previous Study | Return to List | Next Study

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04211831
Recruitment Status : Recruiting
First Posted : December 26, 2019
Last Update Posted : May 21, 2020
Information provided by (Responsible Party):
Urovant Sciences GmbH

Brief Summary:
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder (OAB) and urge urinary incontinence (UUI) up to 48 weeks post-dose.

Condition or disease Intervention/treatment Phase
Overactive Bladder With Urge Urinary Incontinence Drug: URO-902 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence
Actual Study Start Date : December 16, 2019
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Cohort 1: URO-902 24 mg; Placebo
Participants will receive either a single treatment of URO-902 24 milligrams (mg) or matching placebo.
Drug: URO-902
intradetrusor injection
Other Names:
  • hMaxi-K
  • pVAX/hSlo

Drug: Placebo
intradetrusor injection

Experimental: Cohort 2: URO-902 48 mg; Placebo
Participants will receive either a single treatment of URO-902 48 mg or matching placebo.
Drug: URO-902
intradetrusor injection
Other Names:
  • hMaxi-K
  • pVAX/hSlo

Drug: Placebo
intradetrusor injection

Primary Outcome Measures :
  1. Change from Baseline at Week 12 in average daily number of Urge Urinary Incontinence (UUI) episodes [ Time Frame: Baseline; Week 12 ]

Secondary Outcome Measures :
  1. Number of participants with any adverse event [ Time Frame: up to Week 48 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant has symptoms of Overactive Bladder (OAB) (frequency and urgency) with Urge Urinary Incontinence (UUI) for a period of at least 6 months prior to screening.
  • Participant experiences ≥ 1 episode of UUI per day.
  • Participant has not been adequately managed with ≥ 1 oral or transdermal pharmacologic therapies for the treatment of their OAB symptoms.

Exclusion Criteria:

  • Participant has symptoms of OAB due to any known neurological reason (e.g., spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc).
  • Participant has a predominance of stress incontinence in the opinion of the investigator, determined by participant history.
  • Participant currently uses or plans to use medications or therapies to treat symptoms of OAB, including nocturia.
  • Participants who have previously been treated with onabotulinumtoxinA for urological indications within 12 months of starting the Screening Bladder Diary, or any other toxin for urological indications, regardless of when treated (participants treated with onabotulinumtoxinA or other toxins for non-urological indications are eligible, regardless of when treated)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04211831

Layout table for location contacts
Contact: JP Nicandro, PharmD 833-219-5557

Layout table for location information
United States, Alabama
Coastal Clinical Research Inc Recruiting
Mobile, Alabama, United States, 36608
United States, Arizona
Urological Associates of Southern Arizona Recruiting
Tucson, Arizona, United States, 85715
United States, California
Tri Valley Urology Medical Group Not yet recruiting
Murrieta, California, United States, 92562
United States, Florida
Precision Clinical Research LLC Recruiting
Sunrise, Florida, United States, 33351
United States, Iowa
Iowa Clinic Recruiting
West Des Moines, Iowa, United States, 50266
United States, Michigan
Oakland University Wm. Beaumont School of Medicine - Beaumont Health Center Not yet recruiting
Royal Oak, Michigan, United States, 48073
United States, New Jersey
Premier Urology Group, LLC Recruiting
Edison, New Jersey, United States, 08837
United States, New York
Great Lakes Physician PC / Western New York Urology Associates Recruiting
Cheektowaga, New York, United States, 14225
Accumed Research Associates - ClinEdge - PPDS Recruiting
Garden City, New York, United States, 11530
United States, Virginia
Urology of Virginia Recruiting
Virginia Beach, Virginia, United States, 23462
United States, Washington
Washington Urology & Urogynecology Associates Recruiting
Kirkland, Washington, United States, 98034
Sponsors and Collaborators
Urovant Sciences GmbH
Layout table for additonal information
Responsible Party: Urovant Sciences GmbH Identifier: NCT04211831    
Other Study ID Numbers: URO-902-2001
First Posted: December 26, 2019    Key Record Dates
Last Update Posted: May 21, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Urovant Sciences GmbH:
Overactive Bladder
Urge Urinary Incontinence
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Incontinence
Urinary Bladder, Overactive
Urinary Incontinence, Urge
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Behavioral Symptoms
Elimination Disorders
Mental Disorders
Urinary Bladder Diseases